Biopharma, Doctors, FDA and Side effects

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Biopharma

Doctors

FDA

Side effects

Targeting tumours with novel radiopharmaceuticals

European Pharmaceutical Review

OCTOBER 19, 2023

billion deal, in which Eli Lilly agreed to acquire two of POINT Biopharma Global’s late-stage radioligand therapies for oncological indications. This has been demonstrated recently with PLUVICTO ® , which was the first US Food and Drug Administration (FDA)-approved targeted radioligand therapy for eligible patients with prostate cancer.

Food and Drug Administration

Food and Drug Administration Side effects Manufacturing Doctors

How to Work with Patient Advocates, Influencers, and Ambassadors

PM360

JUNE 11, 2022

For example, everyone must be steeped in both FDA and FTC guidelines. Regardless of the tactics and strategies employed, I would encourage more biopharma professionals to get personally involved in patient engagement programs. Once you choose a patient partner, transparency is tantamount to building a successful working relationship.

Patients

Patients Pharma Education Media

Pharma Rep Focus

Targeting tumours with novel radiopharmaceuticals

How to Work with Patient Advocates, Influencers, and Ambassadors

Stay Connected